PBI’s primary technology uses self-adjuvanting DNA vaccines administered with a heterologous booster immunization to achieve a safe and effective immunotherapeutic response. (1) Adjuvant-free DNA vaccines (2) Heterologous prime-boost immunization schedule (3) Simple, local delivery
